Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Department of Epidemiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China; The Fujian Cancer Prevention and Control Office, Fuzhou, China.
Cancer Epidemiol. 2024 Oct;92:102641. doi: 10.1016/j.canep.2024.102641. Epub 2024 Aug 20.
To analyze the survival outcomes of female patients with cervical, uterine, and ovarian cancers in Southeast China (Fujian Province) from 2011 to 2020 and to provide a reference basis for prognostic evaluation and prevention of gynecological malignancies.
The data of 5823 patients with cervical, uterine, and ovarian cancers registered in the Fujian Provincial Cancer Prevention and Control System from 2011 to 2020 were enrolled for survival analysis and further stratified by age at diagnosis and township. Survival time was calculated up to March 30, 2022, and relative survival (RS) and age-standardized RS were calculated according to the International Cancer Survival Standards (ICSS).
During 2011-2015, the 5-year RS for cervical, uterine, and ovarian cancers were 64.3 %, 64.2 %, and 44.7 %, respectively, while the age-standardized 5-year RS were 56.8 %, 47.9 %, and 27.9 %, respectively. During 2016-2020, the 5-year RS for cervical, uterine, and ovarian cancers were 72.3 %, 78.9 %, and 50.8 %, respectively, while the age-standardized 5-year RS were 64.5 %, 54.6 %, and 34.2 %, respectively. The 5-year RS for cervical and ovarian cancer all declined with age, while the 5-year RS for uterine cancer was highest at 45-54 years and lowest at 75 years. In addition, survival rates were broadly higher in urban than rural areas.
Survival rates for cervical, uterine, and ovarian cancers have generally increased in the population covered by the Fujian Cancer Registry. However, survival rates remain lower than in developed countries. Emphasis should be placed on gynecological cancer screening and the introduction of effective treatments to improve survival rates for gynecological cancers.
分析 2011 年至 2020 年中国东南部（福建省）女性宫颈癌、子宫癌和卵巢癌患者的生存结果，并为妇科恶性肿瘤的预后评估和预防提供参考依据。
对 2011 年至 2020 年福建省癌症防治系统登记的 5823 例宫颈癌、子宫癌和卵巢癌患者进行生存分析，并按诊断年龄和乡镇进一步分层。生存时间计算至 2022 年 3 月 30 日，根据国际癌症生存标准（ICSS）计算相对生存率（RS）和年龄标准化 RS。
2011-2015 年，宫颈癌、子宫癌和卵巢癌的 5 年 RS 分别为 64.3%、64.2%和 44.7%，年龄标准化 5 年 RS 分别为 56.8%、47.9%和 27.9%。2016-2020 年，宫颈癌、子宫癌和卵巢癌的 5 年 RS 分别为 72.3%、78.9%和 50.8%，年龄标准化 5 年 RS 分别为 64.5%、54.6%和 34.2%。宫颈癌和卵巢癌的 5 年 RS 均随年龄增长而下降，而子宫癌的 5 年 RS 在 45-54 岁时最高，75 岁时最低。此外，城市地区的生存率普遍高于农村地区。
福建省癌症登记覆盖人群中，宫颈癌、子宫癌和卵巢癌的生存率总体呈上升趋势，但仍低于发达国家。应重视妇科癌症筛查和有效治疗方法的引入，以提高妇科癌症的生存率。
